Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $201.45 | Total: $1,007.25 |
| 1 | 10 | $170.64 | Total: $1,706.40 |
| 1 | 25 | $144.57 | Total: $3,614.25 |
| 1 | 50 | $123.24 | Total: $6,162.00 |
| 1 | 100 | $106.65 | Total: $10,665.00 |
Overview
EZM0414 is a potent and selective, orally bioavailable inhibitor of SETD2 with an IC50 of 18 nM in biochemical assays and 34 nM in cellular assays, potentially useful for researching relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma [1].
Chemical Properties
| Molecular Formula | C22H29FN4O2 |
| Molecular Weight | 400.49 |
| CAS Numbers | 2411748-50-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [H][C@@]1(CCC[C@H](C1)NC(=O)c1cc2c(F)ccc(C)c2[nH]1)N1CCN(CC1)C(C)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Jennifer Totman, et al. Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-cell Lymphoma.